retatrutide diabetes type 2 Shows Promise in Treating | Fikreab Tesfaye Tefera posted on the topic Triple hormone receptor agonist retatrutide

One of the key issues contributing to the high cost of medications, including GLP-1s that are in a formulary (a list of medications covered by a health plan), is a lack of price transparency

Unlike traditional oral supplements that rely on the digestive system, PatchMDs transdermal patches deliver nutrients directly through the skin, avoiding potential gastrointestinal discomfort and absorption issues

Common adverse effects of GLP-1 receptor agonists include: Gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation) Injection site reactions Headache Fatigue Dizziness Important safety considerations include: Risk of hypoglycaemia when used with insulin or sulfonylureas (dose reduction of these agents may be needed) Potential worsening of diabetic retinopathy with semaglutide in patients with pre-existing retinopathy Risk of dehydration and acute kidney injury from persistent vomiting or diarrhoea Pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies, though human relevance remains uncertain) Patients should be counselled about persistent severe abdominal pain as a potential warning sign of pancreatitis requiring immediate medical attention

In addition to appetite regulation, GLP-1 improves how the body uses insulin, making it especially valuable for patients with diabetes or prediabetes